Pharmabiz8h
GSK announces positive results from GLISTEN phase III trial of linerixibat in adults with cholestatic pruritus (relentless itch) associated with PBC
GSK announces positive results from GLISTEN phase III trial of linerixibat in adults with cholestatic pruritus (relentless itch) associated with PBC: London, UK Wednesday, Novembe ...
Chemomab highlights clincial activity of CM-101 at The Liver Meeting 2024
Chemomab Therapeutics (CMMB) announced that data from its Phase 2 SPRING trial in patients with primary sclerosing cholangitis was presented at ...
ENDPOINTS NEWS16h
GSK plots reg­u­la­to­ry fil­ings for PBC itch af­ter pos­i­tive Phase 3 read­out
GSK’s linerixibat helped reduce itch in patients with a rare bile duct disease, meeting its primary endpoint in a late-stage ...
GSK's Investigational Liver Disease Candidate Hits Primary Goal In Late-Stage Study To Treat Relentless Itch In Some Patients
On Tuesday, GSK plc (NYSE:GSK) released the headline results of the GLISTEN global phase 3 trial evaluating linerixibat in ...
GSK reports positive Phase 3 results for linerixibat in PBC itching
GSK (NYSE:GSK) said a Phase 3 study of its drug linerixibat in the treatment of relentless itching in patients with primary ...
The Pharma Letter22h
Linerixibat shows positive Phase III results in PBC, says GSK
UK pharma major GSK today announced positive headline results of GLISTEN, the ongoing global Phase III clinical trial ...